Physician profile
Chad C Spangler
NPI 1073625562
$30,086.34
in general payments reported to CMS, 2019-2025
36 companies · $1,822 in 2025
The $1,822 reported for 2025 was more than what 77% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $6,115 · 2021: $485 · 2022: $775 · 2023: $891 · 2024: $1,169 · 2025: $1,822.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,882.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,881.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $24,914.03 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Janssen Biotech, INC. | $581.85 | 2019-2025 | Tremfya, Stelara, Remicade |
| Saranas, INC. | $541.85 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $432.39 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Genzyme Corporation | $361.26 | 2022-2025 | |
| Pfizer INC. | $278.38 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $250.79 | 2019-2025 | Xifaxan, Trulance |
| Madrigal Pharmaceuticals | $228.51 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $212.47 | 2019-2025 | |
| Celgene Corporation | $199.57 | 2022-2024 | Zeposia |
| Ipsen Biopharmaceuticals, INC | $197.00 | 2024-2025 | Iqirvo |
| Regeneron Healthcare Solutions, INC. | $179.27 | 2023-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $168.48 | 2019-2024 | Dificid |
| Apollo Endosurgery US INC | $136.25 | 2023 | Overstitch Endoscopic Suturing System |
| Vivus LLC | $128.24 | 2024-2025 | Pancreaze |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $124.86 | 2019-2025 | |
| Braintree Laboratories, INC. | $111.99 | 2019-2025 | Sutab, Suflave |
| Qol Medical, LLC | $111.88 | 2019-2025 | Sucraid |
| Ferring Pharmaceuticals INC. | $105.56 | 2019-2025 | Rebyota |
| Boston Scientific Corporation | $98.35 | 2019-2022 | |
| Ardelyx, INC. | $90.31 | 2023-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $83.36 | 2025 | Voquezna |
| Celltrion USA INC. | $70.01 | 2025 | Vegzelma |
| Biocon Biologics INC | $64.31 | 2024-2025 | Hulio, Yesintek |
| Ucb, INC. | $63.83 | 2019-2020 | |
| Lilly USA, LLC | $52.95 | 2024 | Omvoh |
| Romark Laboratories, Lc | $51.43 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $45.45 | 2022 | |
| Ironwood Pharmaceuticals, INC | $45.32 | 2019-2023 | Linzess |
| Fresenius Kabi USA, LLC | $32.60 | 2023 | |
| Abiomed | $28.61 | 2024 | Impella |
| Aimmune Therapeutics, INC. | $26.01 | 2025 | Zenpep |
| Nestle Healthcare Nutrition INC. | $22.31 | 2022 | |
| Mirum Pharmaceuticals, INC. | $21.98 | 2025 | Livmarli |
| Shionogi INC | $13.29 | 2020 | |
| Allergan, INC. | $11.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Spangler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.